Literature DB >> 17478000

Octaarginine-modified multifunctional envelope-type nano device for siRNA.

Yoshio Nakamura1, Kentaro Kogure, Shiroh Futaki, Hideyoshi Harashima.   

Abstract

The multifunctional envelope-type nano device (MEND) is a novel non-viral gene delivery system for plasmid DNA (pDNA) and oligodeoxynucleotides (ODN). We showed previously that octaarginine-modified MEND (R8-MEND) produces a high transfection activity without cytotoxicity via macropinocytosis and efficient release of a condensed DNA core to the cytosol. In the present study, we succeeded in developing an efficient method for packaging siRNA into the R8-MEND, and its silencing effect was compared with that of transfection reagent TransIT-TKO. A polycation able to condense siRNA was screened for by measuring the size and zeta-potential of complexes formed between siRNA and the polycations poly-l-lysine (PLL), stearyl octaarginine (STR-R8) and protamine. Only STR-R8 was able to condense siRNA to form nano particles (<100 nm), whereas all three polycations were able to condense pDNA or ODN. The siRNA packaged in R8-MEND inhibited luciferase activity by more than 80% in HeLa cells stably expressing luciferase. Much amount of siRNA was internalized into the cells as R8-MEND, and siRNA was effectively released from lipid envelope of MEND to cytoplasm near the nucleus. Consequently, R8-MEND can deliver condensed siRNA into cells to produce an efficient and persistent silencing effect with minimum cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17478000     DOI: 10.1016/j.jconrel.2007.03.010

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  44 in total

1.  Poly-L-arginine and dextran sulfate-based nanocomplex for epidermal growth factor receptor (EGFR) siRNA delivery: its application for head and neck cancer treatment.

Authors:  Hyun-Jong Cho; Saeho Chong; Suk-Jae Chung; Chang-Koo Shim; Dae-Duk Kim
Journal:  Pharm Res       Date:  2011-12-15       Impact factor: 4.200

Review 2.  Delivery of macromolecules using arginine-rich cell-penetrating peptides: ways to overcome endosomal entrapment.

Authors:  Ayman El-Sayed; Shiroh Futaki; Hideyoshi Harashima
Journal:  AAPS J       Date:  2009-01-06       Impact factor: 4.009

3.  Cell-Penetrating Peptides Delivering siRNAs: An Overview.

Authors:  Luca Falato; Maxime Gestin; Ülo Langel
Journal:  Methods Mol Biol       Date:  2021

4.  A peptide-based vector for efficient gene transfer in vitro and in vivo.

Authors:  Taavi Lehto; Oscar E Simonson; Imre Mäger; Kariem Ezzat; Helena Sork; Dana-Maria Copolovici; Joana R Viola; Eman M Zaghloul; Per Lundin; Pedro M D Moreno; Maarja Mäe; Nikita Oskolkov; Julia Suhorutšenko; C I Edvard Smith; Samir E L Andaloussi
Journal:  Mol Ther       Date:  2011-02-22       Impact factor: 11.454

Review 5.  Composite nanoparticles for gene delivery.

Authors:  Yuhua Wang; Leaf Huang
Journal:  Adv Genet       Date:  2014       Impact factor: 1.944

Review 6.  Progress toward in vivo use of siRNAs-II.

Authors:  Garrett R Rettig; Mark A Behlke
Journal:  Mol Ther       Date:  2011-12-20       Impact factor: 11.454

7.  Effect of lipid headgroup charge and pH on the stability and membrane insertion potential of calcium condensed gene complexes.

Authors:  Nabil A Alhakamy; Ibrahim Elandaloussi; Saba Ghazvini; Cory J Berkland; Prajnaparamita Dhar
Journal:  Langmuir       Date:  2015-03-30       Impact factor: 3.882

Review 8.  Self-assembled lipid nanomedicines for siRNA tumor targeting.

Authors:  Yu-Cheng Tseng; Leaf Huang
Journal:  J Biomed Nanotechnol       Date:  2009-08       Impact factor: 4.099

9.  Recent developments in peptide-based nucleic acid delivery.

Authors:  Sandra Veldhoen; Sandra D Laufer; Tobias Restle
Journal:  Int J Mol Sci       Date:  2008-07-16       Impact factor: 6.208

Review 10.  Peptide-mediated cellular delivery of oligonucleotide-based therapeutics in vitro: quantitative evaluation of overall efficacy employing easy to handle reporter systems.

Authors:  S D Laufer; T Restle
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.